Angiex
Founder, CEO
Angiex was founded in Dec 2015 to create an antibody-drug conjugate therapy for cancer against a novel target on the tumor vasculature, TM4SF1. Angiex is based in LabCentral... more and has licensed IP from Beth Israel Deaconess Medical Center. Seed funding is from Thiel Capital.